Psychedelic drugs like psilocybin and ecstasy are starting to attract attention from investors.
In an exclusive interview with Business Insider, the world’s first psychedelic-focused VC firm shared its plan for seeding promising startups in the space.
Based in Canada, the firm, called Field Trip Ventures, aims to open clinics in the US and partner with existing research groups.
Field Trip’s founders hail from the marijuana investment world. They see psychedelics as “the next wave of the path that’s been created by cannabis,” they said.
Visit Business Insider’s homepage for more stories.
As the legalization of medical cannabis has swept the globe, it’s also paved the way for another new health frontier: psychedelic medicine.
Once portrayed as an illegal way to “drop out” or “tune in,” psychedelic and semi-psychedelic drugs like psilocybin and ecstasy are starting to turn into federally-regulated medicines. They’re attracting the attention of investors, too.
A number of entrepreneurial backers including Peter Thiel have begun seeding psychedelic research, mostly with the aim of seeing new drugs approved for mental illnesses like depression and anxiety. Clinical trials of psychedelic drugs have blossomed in recent years, and a non-profit initiative called MAPS is currently working with federal …read more
Source:: Businessinsider – Technology